Jasmin Zeindler1, Fiorenzo Angehrn2, Raoul Droeser2, Silvio Däster2, Salvatore Piscuoglio3, Charlotte K Y Ng4, Ergin Kilic5, Robert Mechera2, Samuel Meili2, Andrej Isaak6, Walter P Weber1, Simone Muenst4, Savas Deniz Soysal7,8. 1. Breast Cancer Center, University Hospital Basel and University of Basel, 4031, Basel, Switzerland. 2. Department of Surgery, Clarunis University Center for Gastrointestinal and Liver Diseases Basel, Basel, Switzerland. 3. Visceral Surgery Research Laboratory, Clarunis, Department of Biomedicine, University of Basel, Basel, Switzerland. 4. Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland. 5. Institute of Pathology, Hospital Leverkusen, Leverkusen, Germany. 6. Department of Vascular and Endovascular Surgery, University Hospital Basel, Basel, Switzerland. 7. Department of Surgery, Clarunis University Center for Gastrointestinal and Liver Diseases Basel, Basel, Switzerland. savas.soysal@usb.ch. 8. Visceral Surgery Research Laboratory, Clarunis, Department of Biomedicine, University of Basel, Basel, Switzerland. savas.soysal@usb.ch.
Abstract
PURPOSE: Myeloperoxidase (MPO) is an enzyme secreted by neutrophil granulocytes as a result of phagocytosis during inflammation. In colorectal cancer, tumour infiltration by MPO expressing cells has been shown to be independently associated with a favourable prognosis. In this study, we explored the role of MPO-positive cell infiltration and its prognostic significance in invasive breast cancer. METHODS: We performed immunohistochemical staining for MPO on multiple tissue microarrays comprising a total of 928 human breast cancer samples with detailed clinical-pathological annotation and outcome data. RESULTS: MPO-positive cell infiltration (≥ 5 cells/tissue punch) was found in 150 (16%) of the 928 evaluable breast cancer cases. In univariate survival analyses, infiltration by MPO-positive cells was associated with a significantly better overall survival (p < 0.001). In subset univariate analyses, the infiltration by MPO-positive cells was associated with significantly better overall survival in the Luminal B/HER2-negative subtype (p = 0.005), the HER2 enriched subtype (p = 0.011), and the Triple Negative subtype (p < 0.001). In multivariate analysis, MPO expression proved to be an independent prognostic factor for improved overall survival (p < 0.001). CONCLUSIONS: This is the first study to show that infiltration of MPO-positive cells is an independent prognostic biomarker for improved overall survival in human breast cancer.
PURPOSE:Myeloperoxidase (MPO) is an enzyme secreted by neutrophil granulocytes as a result of phagocytosis during inflammation. In colorectal cancer, tumour infiltration by MPO expressing cells has been shown to be independently associated with a favourable prognosis. In this study, we explored the role of MPO-positive cell infiltration and its prognostic significance in invasive breast cancer. METHODS: We performed immunohistochemical staining for MPO on multiple tissue microarrays comprising a total of 928 humanbreast cancer samples with detailed clinical-pathological annotation and outcome data. RESULTS:MPO-positive cell infiltration (≥ 5 cells/tissue punch) was found in 150 (16%) of the 928 evaluable breast cancer cases. In univariate survival analyses, infiltration by MPO-positive cells was associated with a significantly better overall survival (p < 0.001). In subset univariate analyses, the infiltration by MPO-positive cells was associated with significantly better overall survival in the Luminal B/HER2-negative subtype (p = 0.005), the HER2 enriched subtype (p = 0.011), and the Triple Negative subtype (p < 0.001). In multivariate analysis, MPO expression proved to be an independent prognostic factor for improved overall survival (p < 0.001). CONCLUSIONS: This is the first study to show that infiltration of MPO-positive cells is an independent prognostic biomarker for improved overall survival in humanbreast cancer.
Entities:
Keywords:
Breast cancer; Myeloperoxidase; Prognostic factor; Tumour-associated neutrophils
Authors: Vittorio Branchi; Benedict Jürgensen; Laura Esser; Maria Gonzalez-Carmona; Tobias J Weismüller; Christian P Strassburg; Jonas Henn; Alexander Semaan; Philipp Lingohr; Steffen Manekeller; Glen Kristiansen; Jörg C Kalff; Marieta I Toma; Hanno Matthaei Journal: J Pers Med Date: 2021-03-23
Authors: Luke Hall; Chaouri Guo; Sarah Tandy; Kathryn Broadhouse; Anthony C Dona; Ernst Malle; Emil D Bartels; Christina Christoffersen; Stuart M Grieve; Gemma Figtree; Clare L Hawkins; Michael J Davies Journal: Sci Rep Date: 2021-06-16 Impact factor: 4.379